Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Withdrawn Phase 1 Trials for Beta-D-Glucose (DB02379)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05228249Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaTreatment